Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 1999

View Archived Issues

Positive study results obtained for Andrographolide + AZT

Cortecs discontinues Macritonin development and refocuses resources

Viagra is effective in treating ED in men with depression

NCI scientists on track to develop a vaccine to prevent, treat genital warts and cervical cancer

CombiChem and Icos expand collaboration

AxyS initiates phase II human clinical trials of APC-2059 for treatment of psoriasis

Matrix broadens phase II clinical trial program for FMdC to include colorectal cancer

Maxygen receives milestone payment from Pfizer

BioMarin subsidiary acquires biochemical reagent business from Oxford GlycoSciences

Significant antitumor response shown in preclinical study of prostate cancer treatment

News from DDW: effects of a 5-HT4 receptor antagonist on GI function in volunteers

Astressin B: a potential treatment for stress-induced gastrointestinal disturbances

Alza submits NDA for Viadur prostate cancer treatment

Bayer and Takeda launch cerivastatin in Japan

Zelmac featured in multiple presentations at DDW

Cenestin expected to be available in pharmacies by June 1, 1999

New compounds synthesized at JT promote osteogenesis

Cephalon develops compounds for muscle wasting

DNA ligase inhibitors with alpha-pyrone structure in development at Millennium

Dopamine D4 receptor ligands useful for schizophrenia claimed by Neurogen and Schering-Plough

Merck's new carbapenems particularly active against methicillin-resistant Gram-positive pathogens

Pierre Fabre strengthens R&D programs; company pipeline in review

Novel bicyclic compounds useful for lipid disorders, diabetes, obesity, etc.

New antifungal azole compounds developed in China

Potent new quinolone antibacterial agents synthesized at Shanghai Institute of Materia Medica

New gerontogene discovered by GenoPlex; further study funded by NIH

Survival advantage for exemestane observed in phase III breast cancer trial reported at ASCO meeting

RotaShield vaccine receives marketing authorization in Europe

PD-098059 inhibits AII-induced MAPK activation in myocardial cells

Long-term AT1 receptor blockade with fonsartan proves highly beneficial in SHR-SP

More news from ASCO: safety and pharmacokinetics of squalamine examined in phase I trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...